ClinicalTrials.gg
CompletedNCT02279173Updated Jun 23, 2022Results posted

Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)

A Phase 3 interventional study of Romiplostim in Immune Thrombocytopenia, sponsored by Amgen. Completed at 78 sites in 17 countries. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2022-06-23.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
203
Allocation
Not applicable
Ages
1 Year to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 6 under way, 2 of them phase 3. romiplostim · Purpura, Thrombocytopenic, Idiopathic.

Enrollment
5th of 29
203 · median 62
Started
2014
the only one that year
Phase 3
13 of 29
1 open now
Registered
15th of 29
by date
Lead sponsor
14 of 29
Amgen

Among the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, this one is the 5th largest by enrollment, is the only one that started in 2014, is one of 13 in phase 3, and was the 15th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

5 of the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About romiplostim

romiplostim: first FDA approval 2008 (NPLATE), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 1 Year to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

This is a phase 3b single arm, open label, multicenter study describing the percentage of time pediatric participants with ITP have a platelet response while receiving romiplostim, defined as a platelet count ≥ 50 x 10\^9/L in the absence of ITP rescue medications for the past 4 weeks.

03

Conditions studied

  • Immune Thrombocytopenia

Keywords

  • Pediatric
  • Immune Thrombocytopenia
  • Amgen
04

Who can participate

Ages eligible
1 Year to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of primary ITP according to The American Society of Hematology (ASH) Guidelines at least 6 months before screening, regardless of splenectomy status
  • Age ≥ 1 year and \< 18 years of age
  • to prior ITP therapy, relapsed after at prior ITP therapy, or be ineligible for other therapies. Examples of prior therapy include: , intravenous Immunoglobulin (IVIG), anti-D immunoglobulin, transfusions.
  • Platelet count ≤ 30 x10\^9/L or is experiencing uncontrolled bleeding
  • Has provided before any study-specific procedure;
  • Adequate hematologic, renal, and liver function during screening:

    • > 10.0 g/dL
    • Serum creatinine ≤ 1.5 x the (ULN)
    • Total serum ≤ 1.5 x the ULN
    • (AST) and alanine aminotransferase (ALT) ≤ 3.0 x the ULN
  • For the EU, Switzerland and Turkey protocol supplement, subject must agree to a scheduled bone marrow and aspirate at Year 1 or Year 2 following romiplostim treatment and any unscheduled biopsies if clinically indicated
  • For the EU, Switzerland and Turkey protocol supplement, a reticulin grade of 0, 1, 2, or 3 according to the modified Bauermeister grading scale, as assessed by central laboratory from a bone marrow biopsy performed within 1 year prior to planned first dose of romiplostim or consent to a pre-treatment bone marrow biopsy and aspirate prior to planned first dose of romiplostim

Exclusion criteria

Exclusion Criteria:

  • History of a bone marrow stem cell disorder (Any abnormal bone marrow findings other than those typical of ITP must be approved by Amgen before a subject may be enrolled)
  • Prior bone marrow transplant or peripheral blood progenitor cell transplant
  • Active or prior except non-melanoma skin cancers within the last 5 years
  • History of myelodysplastic syndrome
  • History of bleeding diathesis
  • History of congenital thrombocytopenia
  • History of , or (HIV)
  • History of systemic lupus erythematosus, Evans syndrome, or neutropenia
  • History of antiphospholipid antibody syndrome or known positive for lupus anticoagulant
  • History of disseminated intravascular coagulation, hemolytic uremic syndrome, or thrombotic thrombocytopenic purpura
  • History of venous thromboembolism or thrombotic events
  • Previous use of romiplostim or previous use of eltrombopag within 4 weeks of enrollment
  • Previous use of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), recombinant human thrombopoietin (rHuTPO) or any other producing agent
  • Rituximab (for any indication) or 6-mercaptopurine within 8 weeks of enrollment, or anticipated use at any time during the study
  • Splenectomy within 4 weeks of the screening visit
  • Alkylating agents within 8 weeks before the screening visit or anticipated use during the time of the proposed study
  • Vaccinations known to decrease platelet counts within 8 weeks before the screening visit
  • Currently enrolled in another device or drug study, or less than 30 days since ending investigational study
  • Will have investigational procedures while enrolled on study
  • Female subject of child bearing potential (defined as having first menses) not willing to use, in combination with her partner highly effective methods of during treatment and for 1 month after the end of treatment
  • Subject is pregnant or breast feeding, or might become pregnant within 1 month after the end of treatment
  • Subject has known to any recombinant Escherichia coli derived product (eg, Infergen®, Neupogen®, somatropin, and Actimmune®)
  • Has previously enrolled into this study
  • Will not be available for protocol-required study visits or procedures, to the best of the subject's and investigator's knowledge
  • Any kind of disorder that, may compromise the subject to give written and/or to comply with all required study procedures
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
203 participants (actual)

Study arms

  • Experimental
    Romiplostim

    Participants received romiplostim administered weekly by subcutaneous injection for up to 3 years. The starting dose was 1 µg/kg titrated in 1 µg/kg increments up to a maximum of 10 µg/kg to reach a target platelet count ≥ 50 x 10⁹/L.

    Drug: Romiplostim

Interventions

  • Romiplostim subcutaneous weekly injection

    Also known as: Nplate

06

What researchers measure

Primary outcomes

  1. Percentage of Time With a Platelet Response During the First 6 Months of Treatment

    Platelet response was defined as a platelet count of ≥ 50 x 10⁹/L with no rescue medication use for ITP in the past 4 weeks. Monthly platelet response was calculated based on the median platelet count during each month. For each participant, the percentage of time with platelet response during the first 6 months was calculated as the number of months a platelet response was observed divided by the total number of months response was assessed.

    Time frame: Week 2 to Month 6, platelet response was assessed every week.

  2. Percentage of Participants Who Developed Collagen After Exposure to Romiplostim

    The percentage of participants who developed collagen as evidenced by trichrome staining, defined as a Grade 4 on the modified Bauermeister grading scale: Grade 0: No reticulin fibers demonstrable Grade 1: Occasional fine individual fibers and foci of a fine fiber network Grade 2: Fine fiber network throughout most of the section; no coarse fibers Grade 3: Diffuse fiber network with scattered thick coarse fibers but no mature collagen (negative to trichrome staining) Grade 4: Diffuse, often course fiber network with areas of collagenization (positive trichrome staining)

    Time frame: Year 1 (Cohort 1) and year 2 (Cohort 2)

  3. Percentage of Participants With Increased Modified Bauermeister Grade

    The percentage of participants with an increased modified Bauermeister grade defined as an increase by ≥ 2 severity grades or an increase to grade 4 (i.e., grade 0 to 2-4, grade 1 to 3-4, grade 2 to 4, or grade 3 to 4 over baseline). The modified Bauermeister grading scale: Grade 0: No reticulin fibers demonstrable Grade 1: Occasional fine individual fibers and foci of a fine fiber network Grade 2: Fine fiber network throughout most of the section; no coarse fibers Grade 3: Diffuse fiber network with scattered thick coarse fibers but no mature collagen (negative to trichrome staining) Grade 4: Diffuse, often course fiber network with areas of collagenization (positive trichrome staining) Participants without an evaluable baseline result were assumed to have a baseline modified Bauermeister score of 0.

    Time frame: Baseline, year 1 (Cohort 1) and year 2 (Cohort 2)

  4. Percentage of Participants Who Developed Bone Marrow Abnormalities

    The percentage of participants with bone marrow abnormalities (eg, myelodysplastic syndrome, monosomy 7) based on analysis of bone marrow biopsy and aspirate samples using cytogenetics and fluorescence in situ hybridization.

    Time frame: Year 1 (Cohort 1) and year 2 (Cohort 2)

Secondary outcomes

  1. Percentage of Time With a Platelet Response During the Overall Treatment Period

    Platelet response was defined as a platelet count of ≥ 50 x 10⁹/L with no rescue medication use in the past 4 weeks. Monthly platelet response was calculated based on the median platelet count during each month. For each participant, the percentage of time with platelet response was calculated as the number of months a platelet response was observed divided by the total number of months response was assessed.

    Time frame: From week 2 to the end of the treatment period, 36 months

  2. Percentage of Time With an Increase in Platelet Count ≥ 20 x 10⁹ Cells/L Above Baseline

    The percentage of time with an increase in platelet count ≥ 20 x 10⁹ cells/L above baseline from week 2 until the end of the treatment period without rescue medication use within the past 4 weeks. For each participant, the percentage of time with an increase in platelet count ≥ 20 x10⁹ cells/L above baseline was calculated as the number of months the median platelet count was ≥ 20 x10⁹ cells/L above baseline divided by the total number of months assessed.

    Time frame: Baseline and from week 2 to month 36

  3. Number of Participants Reporting Use of Rescue Medications for ITP During the Treatment Period

    Rescue medication is defined as any medication or transfusion, other than romiplostim and excluded medications, that is administered after enrollment to the participant with the intent of raising platelet counts or to prevent bleeding and includes concomitant medications for ITP in which the dose and/or schedule was increased. Permitted rescue medications included the following: * corticosteroids * platelet transfusions * Intravenous immunoglobulin (IVIG) * azathioprine * anti-D immunoglobulin * danazol

    Time frame: From first dose of romiplostim to the end of the treatment period, 36 months

  4. Number of Participants Who Developed Anti-Romiplostim or Anti-Thrombopoietin Neutralizing Antibodies

    Blood samples were first tested for the presence of binding antibodies to romiplostim or the peptide portion of romiplostim, and to endogenous thrombopoietin (eTPO). Samples testing positive for binding antibodies were then tested for neutralizing antibodies by assessing their ability to neutralize romiplostim and/or eTPO in a cell-based bioassay. Participants who developed neutralizing antibodies are those who had a postbaseline positive result with a negative or no result at baseline. Transient is defined as a negative result at the participant's last time point tested within the study period.

    Time frame: Week 12, week 52 and every 24 weeks thereafter up to month 36

  5. Number of Participants With Adverse Events

    An adverse event (AE) was defined as any untoward medical occurrence in a clinical trial participant, which does not necessarily have a causal relationship with study treatment. A serious adverse event (SAE) was defined as an AE that met at least 1 of the following criteria: * fatal * life threatening * required in-patient hospitalization or prolongation of existing hospitalization * resulted in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event Adverse events were graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 grading scale, where Grade 1 = mild AE; Grade 2 = moderate AE; Grade 3 = severe AE; Grade 4 = life-threatening or disabling; Grade 5 = death related to AE.

    Time frame: SAEs were collected from Screening through end-of-study follow-up (up to 38 months). Nonserious AEs were collected from first to last dose of study drug during the treatment period (up to 36 months).

  6. Percentage of Participants Who Developed Increased Reticulin

    The percentage of participants with increased reticulin as evidenced by silver staining and defined as any increase from baseline in the modified Bauermeister grade: Grade 0: No reticulin fibers demonstrable Grade 1: Occasional fine individual fibers and foci of a fine fiber network Grade 2: Fine fiber network throughout most of the section; no coarse fibers Grade 3: Diffuse fiber network with scattered thick coarse fibers but no mature collagen (negative to trichrome staining) Grade 4: Diffuse, often course fiber network with areas of collagenization (positive trichrome staining) Participants without an evaluable baseline result were assumed to have a baseline modified Bauermeister score of 0.

    Time frame: Baseline, year 1 (Cohort 1) and year 2 (Cohort 2)

07

Results

Posted Aug 28, 2019

Participant flow

Children with immune thrombocytopenic purpura (ITP) and platelet counts ≤ 30×10⁹/L or uncontrolled bleeding were enrolled from December 2014 to August 2016 at 66 centers in 16 countries worldwide, including Eastern Europe (44%), Western Europe (25%), and US/Canada (21%).

Participant flow — Overall Study
MilestoneRomiplostim
Started203
Received treatment203
Enrolled under protocol supplement79
Completed109
Not completed94
Withdrew: Protocol-specified criteria67
Withdrew: Withdrawal by subject20
Withdrew: Decision by sponsor4
Withdrew: Lost to follow-up3

Outcome measures

PrimaryPercentage of Time With a Platelet Response During the First 6 Months of Treatment

Platelet response was defined as a platelet count of ≥ 50 x 10⁹/L with no rescue medication use for ITP in the past 4 weeks. Monthly platelet response was calculated based on the median platelet count during each month. For each participant, the percentage of time with platelet response during the first 6 months was calculated as the number of months a platelet response was observed divided by the total number of months response was assessed.

Time frame:
Week 2 to Month 6, platelet response was assessed every week.
Reported as:
Median · percentage of time
Percentage of Time With a Platelet Response During the First 6 Months of Treatment
percentage of timeRomiplostim
Percentage of Time With a Platelet Response During the First 6 Months of Treatment50.00 (16.67 to 83.33)
PrimaryPercentage of Participants Who Developed Collagen After Exposure to Romiplostim

The percentage of participants who developed collagen as evidenced by trichrome staining, defined as a Grade 4 on the modified Bauermeister grading scale: Grade 0: No reticulin fibers demonstrable Grade 1: Occasional fine individual fibers and foci of a fine fiber network Grade 2: Fine fiber network throughout most of the section; no coarse fibers Grade 3: Diffuse fiber network with scattered thick coarse fibers but no mature collagen (negative to trichrome staining) Grade 4: Diffuse, often course fiber network with areas of collagenization (positive trichrome staining)

Time frame:
Year 1 (Cohort 1) and year 2 (Cohort 2)
Reported as:
Number · percentage of participants
Percentage of Participants Who Developed Collagen After Exposure to Romiplostim
percentage of participantsCohort 1Cohort 2
Percentage of Participants Who Developed Collagen After Exposure to Romiplostim0.0 (0.0 to 12.8)0.0 (0.0 to 9.7)
SecondaryPercentage of Time With a Platelet Response During the Overall Treatment Period

Platelet response was defined as a platelet count of ≥ 50 x 10⁹/L with no rescue medication use in the past 4 weeks. Monthly platelet response was calculated based on the median platelet count during each month. For each participant, the percentage of time with platelet response was calculated as the number of months a platelet response was observed divided by the total number of months response was assessed.

Time frame:
From week 2 to the end of the treatment period, 36 months
Reported as:
Median · percentage of time
Percentage of Time With a Platelet Response During the Overall Treatment Period
percentage of timeRomiplostim
Percentage of Time With a Platelet Response During the Overall Treatment Period78.21 (26.67 to 90.39)
SecondaryPercentage of Time With an Increase in Platelet Count ≥ 20 x 10⁹ Cells/L Above Baseline

The percentage of time with an increase in platelet count ≥ 20 x 10⁹ cells/L above baseline from week 2 until the end of the treatment period without rescue medication use within the past 4 weeks. For each participant, the percentage of time with an increase in platelet count ≥ 20 x10⁹ cells/L above baseline was calculated as the number of months the median platelet count was ≥ 20 x10⁹ cells/L above baseline divided by the total number of months assessed.

Time frame:
Baseline and from week 2 to month 36
Reported as:
Median · percentage of time
Percentage of Time With an Increase in Platelet Count ≥ 20 x 10⁹ Cells/L Above Baseline
percentage of timeRomiplostim
Percentage of Time With an Increase in Platelet Count ≥ 20 x 10⁹ Cells/L Above Baseline80.13 (39.13 to 92.31)
SecondaryNumber of Participants Reporting Use of Rescue Medications for ITP During the Treatment Period

Rescue medication is defined as any medication or transfusion, other than romiplostim and excluded medications, that is administered after enrollment to the participant with the intent of raising platelet counts or to prevent bleeding and includes concomitant medications for ITP in which the dose and/or schedule was increased. Permitted rescue medications included the following: * corticosteroids * platelet transfusions * Intravenous immunoglobulin (IVIG) * azathioprine * anti-D immunoglobulin * danazol

Time frame:
From first dose of romiplostim to the end of the treatment period, 36 months
Reported as:
Count of participants · Participants
Number of Participants Reporting Use of Rescue Medications for ITP During the Treatment Period
ParticipantsRomiplostim
Number of Participants Reporting Use of Rescue Medications for ITP During the Treatment Period60
SecondaryNumber of Participants Who Developed Anti-Romiplostim or Anti-Thrombopoietin Neutralizing Antibodies

Blood samples were first tested for the presence of binding antibodies to romiplostim or the peptide portion of romiplostim, and to endogenous thrombopoietin (eTPO). Samples testing positive for binding antibodies were then tested for neutralizing antibodies by assessing their ability to neutralize romiplostim and/or eTPO in a cell-based bioassay. Participants who developed neutralizing antibodies are those who had a postbaseline positive result with a negative or no result at baseline. Transient is defined as a negative result at the participant's last time point tested within the study period.

Time frame:
Week 12, week 52 and every 24 weeks thereafter up to month 36
Reported as:
Count of participants · Participants
Number of Participants Who Developed Anti-Romiplostim or Anti-Thrombopoietin Neutralizing Antibodies
ParticipantsRomiplostim
Anti-romiplostim neutralizing antibodies7
Transient anti-romiplostim neutralizing antibodies4
Anti-eTPO neutralizing antibodies1
Transient anti-eTPO neutralizing antibodies1
SecondaryNumber of Participants With Adverse Events

An adverse event (AE) was defined as any untoward medical occurrence in a clinical trial participant, which does not necessarily have a causal relationship with study treatment. A serious adverse event (SAE) was defined as an AE that met at least 1 of the following criteria: * fatal * life threatening * required in-patient hospitalization or prolongation of existing hospitalization * resulted in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event Adverse events were graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 grading scale, where Grade 1 = mild AE; Grade 2 = moderate AE; Grade 3 = severe AE; Grade 4 = life-threatening or disabling; Grade 5 = death related to AE.

Time frame:
SAEs were collected from Screening through end-of-study follow-up (up to 38 months). Nonserious AEs were collected from first to last dose of study drug during the treatment period (up to 36 months).
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsRomiplostim
Any adverse event (AE)193
Serious adverse events (SAE)60
AEs leading to discontinuation of romiplostim15
Adverse event Grade ≥ 366
Adverse event Grade ≥ 419
Adverse event Grade ≥ 50
Treatment-related adverse events (TRAE)56
Treatment-related serious adverse events8
TRAEs leading to discontinuation of romiplostim8
Treatment-related adverse events Grade ≥ 38
Treatment-related adverse events Grade ≥ 40
Treatment-related adverse events Grade ≥ 50
PrimaryPercentage of Participants With Increased Modified Bauermeister Grade

The percentage of participants with an increased modified Bauermeister grade defined as an increase by ≥ 2 severity grades or an increase to grade 4 (i.e., grade 0 to 2-4, grade 1 to 3-4, grade 2 to 4, or grade 3 to 4 over baseline). The modified Bauermeister grading scale: Grade 0: No reticulin fibers demonstrable Grade 1: Occasional fine individual fibers and foci of a fine fiber network Grade 2: Fine fiber network throughout most of the section; no coarse fibers Grade 3: Diffuse fiber network with scattered thick coarse fibers but no mature collagen (negative to trichrome staining) Grade 4: Diffuse, often course fiber network with areas of collagenization (positive trichrome staining) Participants without an evaluable baseline result were assumed to have a baseline modified Bauermeister score of 0.

Time frame:
Baseline, year 1 (Cohort 1) and year 2 (Cohort 2)
Reported as:
Number · percentage of participants
Percentage of Participants With Increased Modified Bauermeister Grade
percentage of participantsCohort 1Cohort 2
Percentage of Participants With Increased Modified Bauermeister Grade3.7 (0.1 to 19.0)0.0 (0.0 to 9.7)
PrimaryPercentage of Participants Who Developed Bone Marrow Abnormalities

The percentage of participants with bone marrow abnormalities (eg, myelodysplastic syndrome, monosomy 7) based on analysis of bone marrow biopsy and aspirate samples using cytogenetics and fluorescence in situ hybridization.

Time frame:
Year 1 (Cohort 1) and year 2 (Cohort 2)
Reported as:
Number · percentage of participants
Percentage of Participants Who Developed Bone Marrow Abnormalities
percentage of participantsCohort 1Cohort 2
Percentage of Participants Who Developed Bone Marrow Abnormalities0.0 (0.0 to 12.8)0.0 (0.0 to 11.2)
SecondaryPercentage of Participants Who Developed Increased Reticulin

The percentage of participants with increased reticulin as evidenced by silver staining and defined as any increase from baseline in the modified Bauermeister grade: Grade 0: No reticulin fibers demonstrable Grade 1: Occasional fine individual fibers and foci of a fine fiber network Grade 2: Fine fiber network throughout most of the section; no coarse fibers Grade 3: Diffuse fiber network with scattered thick coarse fibers but no mature collagen (negative to trichrome staining) Grade 4: Diffuse, often course fiber network with areas of collagenization (positive trichrome staining) Participants without an evaluable baseline result were assumed to have a baseline modified Bauermeister score of 0.

Time frame:
Baseline, year 1 (Cohort 1) and year 2 (Cohort 2)
Reported as:
Number · percentage of participants
Percentage of Participants Who Developed Increased Reticulin
percentage of participantsCohort 1Cohort 2
Percentage of Participants Who Developed Increased Reticulin18.5 (6.3 to 38.1)47.2 (30.4 to 64.5)

Adverse events

Collected over SAEs were collected from Screening through end-of-study follow-up (up to 38 months). Nonserious AEs were collected from first to last dose of study drug during the treatment period (up to 36 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Romiplostim0/203 (0%)60/203 (29.6%)183/203 (90.1%)
Most frequent serious events
Showing 10 of 53
Most frequent serious events
EventRomiplostim
EpistaxisRespiratory, thoracic and mediastinal disorders12/203
Platelet count decreasedInvestigations10/203
ThrombocytopeniaBlood and lymphatic system disorders4/203
Neutralising antibodies positiveInvestigations4/203
Immune thrombocytopenic purpuraBlood and lymphatic system disorders3/203
AnaemiaBlood and lymphatic system disorders2/203
Abdominal painGastrointestinal disorders2/203
InfluenzaInfections and infestations2/203
HeadacheNervous system disorders2/203
PresyncopeNervous system disorders2/203
Most frequent other events
Showing 10 of 40
Most frequent other events
EventRomiplostim
HeadacheNervous system disorders78/203
EpistaxisRespiratory, thoracic and mediastinal disorders77/203
NasopharyngitisInfections and infestations75/203
PyrexiaGeneral disorders65/203
CoughRespiratory, thoracic and mediastinal disorders52/203
PetechiaeSkin and subcutaneous tissue disorders48/203
VomitingGastrointestinal disorders47/203
HaematomaVascular disorders42/203
RhinitisInfections and infestations40/203
ContusionInjury, poisoning and procedural complications40/203

Baseline characteristics

All enrolled participants

Age, Continuous
Age, Continuous(years)Romiplostim
Median10.0 (1 to 17)
Age, Customized
Age, Customized(Participants)Romiplostim
≥ 1 to < 6 years49
≥ 6 to < 12 years81
≥ 12 to < 18 years73
Sex: Female, Male
Sex: Female, Male(Participants)Romiplostim
Female103
Male100
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Romiplostim
American Indian or Alaska Native4
Asian12
Black or African American11
Multiple1
Native Hawaiian or Other Pacific Islander0
Other, Not Specified11
White164
Years Since ITP Diagnosis
Years Since ITP Diagnosis(years)Romiplostim
Median1.75 (0.5 to 13.8)
Age at ITP Diagnosis
Age at ITP Diagnosis(years)Romiplostim
Median5.97 (0.6 to 17.3)
Splenectomy Done
Splenectomy Done(Participants)Romiplostim
Yes10
No193
Platelet Count
Platelet Count(10⁹ cells/L)Romiplostim
Median14.00 (1.5 to 265.0)

1 further baseline measures are reported on the registry.

08

Study locations

78 sites
  • Research Site
    Roseville, California 95661, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Chicago, Illinois 60611, United States
  • Research Site
    Peoria, Illinois 61615, United States
  • Research Site
    Indianapolis, Indiana 46260, United States
  • Research Site
    Iowa City, Iowa 52242, United States
  • Research Site
    Kansas City, Missouri 64108, United States
  • Research Site
    Las Vegas, Nevada 89109, United States
  • Research Site
    New York, New York 10021, United States
  • Research Site
    Cincinnati, Ohio 45229, United States
  • Research Site
    Columbus, Ohio 43205, United States
  • Research Site
    Pittsburgh, Pennsylvania 15224, United States
  • Research Site
    Nashville, Tennessee 37232, United States
  • Research Site
    Dallas, Texas 75390, United States
  • Research Site
    Fort Worth, Texas 76104, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Randwick, New South Wales 2031, Australia
  • Research Site
    South Brisbane, Queensland 4101, Australia
  • Research Site
    Parkville, Victoria 3052, Australia
  • Research Site
    Brussels, 1020, Belgium
  • Research Site
    Bruxelles, 1200, Belgium
  • Research Site
    Gent, 9000, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Liege, 4000, Belgium
  • Research Site
    Belem, Pará 66033-000, Brazil
  • Research Site
    Jau, São Paulo 17210-120, Brazil
  • Research Site
    Sao Paulo, São Paulo 05403-000, Brazil
  • Research Site
    Sao Paulo, São Paulo 08270-070, Brazil
  • Research Site
    Hamilton, Ontario L8S 4K1, Canada
  • Research Site
    Toronto, Ontario M5G 1X8, Canada
  • Research Site
    Montreal, Quebec H3T 1C5, Canada
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
  • Research Site
    Olomouc, 775 20, Czechia
  • Research Site
    Ostrava-Poruba, 708 52, Czechia
  • Research Site
    Praha 5, 150 06, Czechia
  • Research Site
    Montpellier cedex 05, 34295, France
  • Research Site
    Nice Cedex 3, 06202, France
  • Research Site
    Paris, 75019, France
  • Research Site
    Vandoeuvre les Nancy, 54511, France
  • Research Site
    Budapest, 1094, Hungary
  • Research Site
    Debrecen, 4032, Hungary
  • Research Site
    Szeged, 6720, Hungary
  • Research Site
    Beer Sheva, 84101, Israel
  • Research Site
    Haifa, 31096, Israel
  • Research Site
    Jerusalem, 91120, Israel
  • Research Site
    Petach Tikvah, 49202, Israel
  • Research Site
    Tel Aviv, 64239, Israel
  • Research Site
    Tel Hashomer, 52621, Israel
  • Research Site
    Monterrey, Nuevo León 64460, Mexico
  • Research Site
    Bydgoszcz, 85-094, Poland
  • Research Site
    Lodz, 91-738, Poland
  • Research Site
    Olsztyn, 10-561, Poland
  • Research Site
    Zabrze, 41-800, Poland
  • Research Site
    Krasnodar, 350007, Russian Federation
  • Research Site
    Moscow, 117198, Russian Federation
  • Research Site
    Moscow, 117997, Russian Federation
  • Research Site
    Saint-Petersburg, 197022, Russian Federation
  • Research Site
    Saratov, 410028, Russian Federation
  • Research Site
    Volgograd, 400138, Russian Federation
  • Research Site
    Johannesburg, Gauteng 2013, South Africa
  • Research Site
    Parktown, Gauteng 2193, South Africa
  • Research Site
    Durban, KwaZulu-Natal 4001, South Africa
  • Research Site
    Tygerberg, Western Cape 7505, South Africa
  • Research Site
    Barcelona, Cataluña 08035, Spain
  • Research Site
    Esplugues de Llobregat, Cataluña 08950, Spain
  • Research Site
    Valencia, Comunidad Valenciana 46026, Spain
  • Research Site
    Madrid, 28009, Spain
  • Research Site
    Madrid, 28046, Spain
  • Research Site
    Basel, 4056, Switzerland
  • Research Site
    St. Gallen, 9006, Switzerland
  • Research Site
    Zuerich, 8032, Switzerland
  • Research Site
    Adana, 01130, Turkey
  • Research Site
    Antalya, 07059, Turkey
  • Research Site
    Izmir, 35100, Turkey
  • Research Site
    Birmingham, B4 6NH, United Kingdom
  • Research Site
    Edinburgh, EH9 1LF, United Kingdom
  • Research Site
    London, W12 0HS, United Kingdom
  • Research Site
    Manchester, M13 9WL, United Kingdom
09

References and documents

Publications

  • Tarantino MD, Despotovic J, Roy J, Grainger J, Cooper N, Beam D, Raj A, Maschan A, Kim J, Eisen M. Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials. Pediatr Blood Cancer. 2020 Nov;67(11):e28630. doi: 10.1002/pbc.28630. Epub 2020 Sep 9. PubMed 32902132 ↗
  • Grainger J, Bussel J, Tarantino M, Cooper N, Beam D, Despotovic J, Maschan A, Wang K, Eisen M, Bowers C. A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia. Blood Adv. 2023 Feb 14;7(3):396-405. doi: 10.1182/bloodadvances.2021006014. PubMed 35413092 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2014 to primary completion in Aug 2018, 44 months.

Results were first posted in Aug 2019, 11 months after primary completion. A results delay was requested in Oct 2017.

Of 41 industry-sponsored phase 3 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 44. This study's 44 months is above that.

Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 22 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2014
First posted
Oct 30, 2014
StartActual
Dec 10, 2014
Primary completionActual
Aug 30, 2018
CompletionActual
Aug 8, 2019
Results delay requested
Oct 2, 2017
Results first posted
Aug 28, 2019
Last update
Jun 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02279173
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Oct 30, 2014
Start date
Dec 10, 2014
Primary completion
Aug 30, 2018
Completion
Aug 8, 2019
Results posted
Aug 28, 2019
Last update
Jun 23, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romiplostim

Start the discussion